Skip to main content
Botany 3% exam weight

Topic 4

Part of the FMGE study roadmap. Botany topic pharma-004 of Botany.

CNS Pharmacology - Sedatives, Hypnotics, and Anxiolytics

🟢 Lite — Quick Review (1h–1d)

Rapid summary for last-minute revision before your exam.

CNS Pharmacology - Sedatives, Hypnotics, and Anxiolytics — Key Facts for FMGE Core concept: Benzodiazepines enhance GABA-A receptor function; barbiturates also enhance GABA but at a different site; both cause CNS depression High-yield point: Flumazenil is the benzodiazepine antagonist; benzodiazepines are safer than barbiturates (less respiratory depression, less addiction) ⚡ Exam tip: Benzodiazepine + alcohol = potentiated CNS depression = dangerous; benzodiazepines are used for alcohol withdrawal and status epilepticus


🟡 Standard — Regular Study (2d–2mo)

Standard content for students with a few days to months.

CNS Pharmacology - Sedatives, Hypnotics, and Anxiolytics — FMGE Study Guide

GABAergic Transmission

GABA-A Receptors

  • Pentameric chloride channel: 2α, 2β, 1γ (or δ, ε, π)
  • α and β subunits surround the chloride channel
  • GABA binding site is at α-β interface
  • Benzodiazepine binding site: At α-γ interface (requires both α and γ subunits)
  • Barbiturate binding site: Within the chloride channel (different from BZD site)

Effects of GABA Enhancement

  • Benzodiazepines: Increase frequency of chloride channel opening (not duration)
  • Barbiturates: Increase duration of chloride channel opening
  • Both: Increase chloride conductance → hyperpolarization → neuronal inhibition

Benzodiazepines

Mechanism

  • Bind to benzodiazepine site on GABA-A receptor
  • Increase affinity of GABA for its binding site
  • Result: ↑frequency of chloride channel opening
  • NO effect if GABA is absent (only enhances existing GABA effect - explains better safety profile)

Common Benzodiazepines

Long-acting (t1/2 > 24 hours):

  • Diazepam: t1/2 20-100 hours; active metabolites (desmethyldiazepam, oxazepam); used for status epilepticus, alcohol withdrawal, muscle spasm
  • Chlordiazepoxide: t1/2 long; used for alcohol withdrawal
  • Clonazepam: t1/2 18-50 hours; used for seizures, panic disorder

Intermediate-acting (t1/2 10-24 hours):

  • Lorazepam: t1/2 10-20 hours; glucuronidated (safe in liver disease); used for status epilepticus (IV), alcohol withdrawal
  • Alprazolam: t1/2 12-15 hours; used for panic disorder
  • Temazepam: t1/2 10-18 hours; used for insomnia

Short-acting (t1/2 < 10 hours):

  • Triazolam: t1/2 2-4 hours; used for insomnia (high addiction potential)
  • Midazolam: t1/2 1-4 hours; used for sedation/anesthesia induction, status epilepticus

Uses of Benzodiazepines

  • Anxiety disorders: GAD, panic disorder, social anxiety (longer-acting preferred)
  • Insomnia: Short-term treatment (2-4 weeks)
  • Seizures: Status epilepticus (diazepam, lorazepam IV), seizures (clonazepam)
  • Alcohol withdrawal: Prevents delirium tremens (chlordiazepoxide, lorazepam)
  • Muscle spasm: Diazepam (also used for tetanus)
  • Premedication: Amnesia before procedures
  • Anesthesia: Midazolam for sedation

Adverse Effects

  • CNS depression: Drowsiness, sedation, impaired coordination
  • Anterograde amnesia: Cannot form new memories (useful for procedures)
  • Paradoxical excitement: Disinhibition, aggression (especially in children and elderly)
  • Respiratory depression: When combined with other CNS depressants (alcohol, opioids)
  • Tolerance and dependence: Long-term use leads to physical dependence
  • Withdrawal syndrome: Anxiety, insomnia, seizures, tremor, sweating

Contraindications

  • Pregnancy (especially first trimester - cleft palate risk)
  • Respiratory insufficiency, sleep apnea
  • Severe liver disease (lorazepam safer)
  • Driving/machinery operators
  • History of substance abuse

Overdose Treatment

  • Flumazenil: Competitive antagonist at BZD receptor on GABA-A
  • Half-life shorter than benzodiazepines (requires repeat dosing)
  • Can precipitate seizures in patients with benzodiazepine dependence and in mixed overdoses (TCAs + BZD)

Drug Interactions

  • Additive CNS depression with alcohol, opioids, antihistamines, antipsychotics
  • Enzyme inducers (carbamazepine, phenytoin) increase metabolism of some BZDs
  • Azole antifungals, macrolides inhibit CYP3A4 → increased BZD levels

Barbiturates

Mechanism

  • Bind to barbiturate site on GABA-A receptor (within chloride channel)
  • Prolong chloride channel opening duration
  • Can open channel even without GABA (unlike BZDs - explains higher toxicity)

Classification

Long-acting (used for seizures):

  • Phenobarbital: t1/2 50-120 hours; status epilepticus, seizures, neonatal seizures

Short-acting:

  • Pentobarbital: t1/2 15-50 hours; sedation, seizures
  • Secobarbital: Formerly used for insomnia (largely replaced by BZDs)

Ultra-short acting (anesthetic):

  • Thiopental, Methohexital: IV induction of anesthesia; rapid redistribution → short duration

Uses

  • Seizures: Phenobarbital for status epilepticus and chronic seizure management
  • Anesthesia: Thiopental for induction (rapid onset, redistribution to fat stores)
  • Increased intracranial pressure: Reduce ICP (thiopental coma)

Adverse Effects

  • CNS depression: More profound than BZDs; respiratory depression at therapeutic doses
  • Tolerance: Cross-tolerance with alcohol and BZDs
  • Dependence: Severe withdrawal (similar to alcohol - delirium, seizures)
  • Enzyme induction: Increases hepatic enzyme synthesis → many drug interactions (warfarin, oral contraceptives, steroids)
  • Porphyria attack: Precipitates acute intermittent porphyria (contraindicated)
  • Paradoxical excitement: Sometimes causes agitation instead of sedation

Barbiturate vs Benzodiazepine

FeatureBarbituratesBenzodiazepines
MechanismLonger chloride channel openingIncrease channel frequency
Can open channel aloneYes (even without GABA)No (only enhance GABA)
Respiratory depressionMore severeLess severe
Enzyme inductionYesNo
Tolerance/dependenceMore severeLess severe
AntidoteNoneFlumazenil
Half-lifeVariableVariable
Use in pregnancyAvoidAvoid (esp. first trimester)

Non-Benzodiazepine Hypnotics (Z-drugs)

Zolpidem, Zaleplon, Eszopiclone:

  • Bind to BZ1 (ω1) subunit of GABA-A receptor (relatively selective for brain)
  • Shorter half-life than traditional BZDs
  • Used for insomnia (sleep onset, not maintenance)
  • Less muscle relaxant and anticonvulsant effect than BZDs
  • Same risks: dependence, withdrawal, additive CNS depression with alcohol
  • Flumazenil can reverse zolpidem effects (though less reliably than BZDs)

Antihistamines (H1 blockers)

Diphenhydramine, Hydroxyzine, Promethazine:

  • Cross BBB → sedation
  • Used for insomnia, allergy, motion sickness
  • Anticholinergic side effects
  • Potentiate other CNS depressants

Buspirone

  • 5-HT1A partial agonist
  • Anxiolytic without sedation, dependence, or abuse potential
  • Takes 1-2 weeks for effect (unlike BZDs which work immediately)
  • No cross-tolerance with alcohol/BZDs
  • Used for GAD when sedation is undesirable

Alcohol (Ethanol)

CNS Effects

  • Low dose: Disinhibition (↑dopamine, ↓GABA inhibition)
  • Moderate: Sedation, motor impairment
  • High dose: Respiratory depression, coma, death
  • Acute intoxication: Slurred speech, ataxia, nystagmus, hypotension

Pharmacokinetics

  • Metabolized by alcohol dehydrogenase (ADH) in liver
  • First-pass metabolism (significant)
  • Zero-order kinetics at high concentrations
  • Rate: ~10-15 mL ethanol/hour (one drink/hour)

Chronic Effects

  • CNS depression tolerance (upregulated CYP450)
  • Physical dependence: Severe withdrawal (delirium tremens, seizures)
  • Wernicke-Korsakoff (thiamine deficiency)
  • Fetal Alcohol Syndrome: Growth restriction, facial anomalies, intellectual disability

Drug Interactions

  • Disulfiram inhibits aldehyde dehydrogenase → acetaldehyde accumulation → flushing, nausea, headache (used for alcohol aversion therapy)
  • Additive CNS depression with other sedatives

Content adapted based on your selected roadmap duration. Switch tiers using the selector above.